logo
Plus   Neg
Share
Email

Roche Reports Results From Evrysdi Study In Infants With Type 1 Spinal Muscular Atrophy

Roche reported results from Evrysdi study in infants with type 1 spinal muscular atrophy. The data showed that treatment with Evrysdi at 12 months helped 90% of these infants survive without permanent ventilation and 33% sit without support for at least 5 seconds, which is not normally seen in the natural course of the disease. The treatment with Evrysdi increased the levels of survival of motor neuron protein by a median 1.9-fold from baseline in the high-dose cohort at 12 months.

The FDA approved Evrysdi in 2020 for the treatment of spinal muscular atrophy in adults and children 2 months of age and older. Evrysdi was granted PRIME designation by the European Medicines Agency in 2018.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Canada's Olymel S.E.C./L.P. has recalled around 6,804 pounds of ready-to-eat or RTE ham products for potential contamination with Salmonella Enteritidis, the U.S. Department of Agriculture's Food Safety and Inspection Service or FSIS announced. ViacomCBS Inc. announced plans to combine CBS News and the CBS Television Stations. The journalistic and business operations of both will be combined into one divisional and leadership structure. Neeraj Khemlani and Wendy McMahon were appointed as presidents and co-heads of the newly formed division, effective early next month. Retail major Target Corp. is recalling about 44,350 units of Cat & Jack Baby Heart Ears Rompers, citing choking risks to children, the U.S. Consumer Product Safety Commission said in a statement. The recall involves rompers sold in various sizes from newborn to 24 months. The rompers were manufactured in Vietnam, and sold at Target stores across the United States and online.
Follow RTT